Delcath Systems (DCTH) opened 2026 with Q1 revenue of about US$25.0 million and a basic EPS loss of roughly US$0.03, while trailing twelve month revenue stood at US$90.4 million and basic EPS was US$0.02. Over the past reported periods, quarterly revenue ranged from US$15.1 million in Q4 2024 to US$24.2 million in Q2 2025, with basic EPS moving between a loss of US$0.11 in Q4 2024 and a profit of US$0.08 in Q2 2025. This gives investors a clear view of how top line scale and profitability have been shifting together as margins evolve.

See our full analysis for Delcath Systems.

With the latest figures on the table, the next step is to see how this mix of revenue scale, earnings swings, and emerging profitability lines up with the widely followed narratives around Delcath Systems.

Profitability Flips Positive On A 12 Month View

• On a trailing 12 month basis to Q1 2026, Delcath Systems reported US$90.4 million in revenue and US$0.6 million in net income, compared with a loss of US$26.4 million on US$37.2 million of revenue in the 12 months to Q4 2024.
• What stands out for bullish investors is that this move to a small profit lines up with the bullish narrative that talks about margin expansion and larger treatment volumes, yet the latest single quarter still shows a net loss of US$1.1 million, which means:
  • The bullish idea of sustained margin gains is partly echoed by the trailing 12 month profit, but the Q1 2026 EPS loss of about US$0.03 shows the path is not smooth yet.
  • Revenue in both Q2 2025 and Q1 2026 sat near US$25.0 million, which is consistent with the growth angle in the bullish view, even though earnings have swung between a US$2.7 million profit and a US$1.1 million loss across recent quarters.

Bulls argue that the shift to trailing profitability and higher recent revenues could be a preview of their optimistic long term earnings story, especially if treatment volumes and margins move closer to their expectations. 🐂 Delcath Systems Bull Case

Quarterly Swings Test The Bearish Concerns

• Across the last six reported quarters, quarterly net income has ranged from a loss of US$3.4 million in Q4 2024 to a profit of US$2.7 million in Q2 2025, with Q1 2026 back at a loss of US$1.1 million on US$25.0 million of revenue.
• Bears focus on the idea that higher R&D and complex site activation could limit earnings, and the recent pattern gives them mixed evidence, because:
  • The return to a loss in Q4 2025 and Q1 2026 supports the bearish worry that spending and expansion costs can outweigh revenue, even after a profitable stretch in early and mid 2025.
  • At the same time, the move from US$15.1 million of revenue in Q4 2024 to between roughly US$19.8 million and US$25.0 million in each subsequent quarter suggests that access programs and center growth that bears question are at least aligning with higher sales in the reported numbers.

Skeptics warn that these profit swings show how quickly higher costs or slower site activations can affect earnings, which is exactly the risk they point to in their cautious long term view. 🐻 Delcath Systems Bear Case

Mixed Valuation Signals Around A US$11.24 Share Price

• With the stock at US$11.24, the provided P/S ratio of 4.3x sits above the peer average of 2.7x and the US medical equipment industry at 2.8x, while a quoted DCF fair value of about US$53.69 is much higher than the current price.
• The consensus style narrative highlights strong forecast growth and also flags these valuation tensions, and the data here underlines that split view, because:
  • Forecast revenue growth of about 19% per year and forecast earnings growth of roughly 61.9% per year help explain why a DCF fair value of US$53.69 can screen well above the current price, particularly after the move to a small trailing 12 month profit.
  • At the same time, trading at a higher P/S than peers while still having recent loss making quarters means investors are paying more per dollar of current sales than comparable companies, which fits the concern that the stock is not cheap on simple multiples even with that DCF gap in the background.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Delcath Systems on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and caution has you curious, it makes sense to look at the numbers yourself and move quickly to shape your own view while sentiment is still forming around the key positives that investors are watching, starting with 3 key rewards

See What Else Is Out There

Despite a small profit on the trailing 12 month view, Delcath Systems still faces recent quarterly losses and earnings volatility alongside a higher P/S than peers.

If that mix of choppy profitability and a premium sales multiple leaves you cautious, compare it with stocks screened for stronger value signals using the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.